A new report from Deloitte Access Economics commissioned for the Continence Foundation of Australia, has revealed that the cost of incontinence to Australia in 2023 has increased to $100.4 billion.
Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation ...